Rheumatic diseases are a group of chronic diseases that mainly affect joints, tendons, ligaments, bones and muscle tissues. These diseases can become an important public health problem because they can lead to physical disability. Although the mortality of patients with rheumatic diseases has decreased significantly over the past few decades due to early diagnosis and active and effective treatment, the mortality of patients with rheumatic diseases is still high compared with the normal population. Epidemiological evidence supports a higher mortality may be attributed to higher comorbidity in patients with rheumatic diseases, especially cardiovascular complications such as ischemic heart disease, heart valve disease, cardiomyopathy, pericardial disease and abnormalities in the heart conduction system. Although the mechanism of cardiovascular disease in patients with rheumatic diseases is not fully understood, the risk factors of traditional cardiovascular diseases such as smoking, lack of exercise, high blood pressure, high blood fat, high blood sugar, and persistent chronic inflammation in patients with rheumatic diseases, and side effects of drugs, such as long-term use of glucocorticoids, may be the main cause of cardiovascular diseases in patients with rheumatic diseases. Rheumatic diseases increase the risk of cardiovascular diseases, which is the leading cause of death in patients with rheumatic diseases. Therefore, it is very important to effectively prevent and treat cardiovascular complications. Understanding the comorbid condition of cardiovascular diseases in patients with rheumatic diseases can better help patients to prevent these complications, prolong life and improve their quality of life. Here, we mainly review the common comorbidity of cardiovascular diseases in patients with rheumatic diseases in recent years and the research progress of the pathogenesis and preventive treatment of these comorbid conditions.